

VBC Release Highlights

May 17, 2024

Practice InsightsSM is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS) and Enhancing Oncology Model (EOM).

MIPS Quality Measures Dashboard

Starting Monday, May 20, 2024, the MIPS Quality Measures dashboard will be updated with the 2024 eCQM Value Sets and Benchmarks.

We also updated the % Performance Rate column to ensure the expected value displays.

EOM Quality Measures Dashboard

Prior to this release, the Patient Analysis header was displayed as All Providers instead of Multiple Providers when selecting two or more providers for data analysis. This is now updated, and the header will display as Multiple Providers.

Status of Dashboard Updates for 2024

CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2024 requirements. The measures listed below either have no 2024 update required or have been updated.

Measure	Description
MIPS Quality Measures Dashboard	
#128	BMI (This measure is no longer a MIPS Traditional Measure)
#130	Current Medications
#134	Preventive Care and Screening for Depression and Follow-Up Plan
#143	Pain Intensity Quantified
#374	Closing the Referral Loop
#462	Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy
PIMSH#1	Advance Care Planning in Stage 4 Disease
PIMSH#2	Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure)
PIMSH#4	Patient-Reported Pain Improvement
PIMSH#9	Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH#10	Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs
PIMSH#15	Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)
PIMSH#16	Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center